The Effectiveness of Anti-Nerve Growth Factor Monoclonal Antibodies in the Management of Pain in Osteoarthritis of the Hip and Knee: A PRISMA Systematic Review and Meta-Analysis
| Autor: | Wasim S. Khan, Kendrick To, Jashmitha Rammanohar, K. T. Matthew Seah, James Sutton |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
WOMAC Pain Arthritis Osteoarthritis Placebo Osteoarthritis Hip law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine Nerve Growth Factor medicine Humans Adverse effect Pain Measurement Ontario 030203 arthritis & rheumatology business.industry Antibodies Monoclonal General Medicine Osteoarthritis Knee medicine.disease Jadad scale Treatment Outcome Anesthesiology and Pain Medicine Meta-analysis Neurology (clinical) business 030217 neurology & neurosurgery |
| Zdroj: | Pain Medicine. 22:1185-1204 |
| ISSN: | 1526-4637 1526-2375 |
| Popis: | Objective To conduct a systematic review and meta-analysis of the efficacy of anti-nerve growth factor (NGF) monoclonal antibodies in osteoarthritis pain (hip and knee). Design Grade the evidence for anti-NGF use. Methods An interdisciplinary work group conducted a literature search for anti-NGF use in osteoarthritis. The systematic review was performed in accordance with methods described by the Cochrane collaboration. General inclusion criteria included all osteoarthritis trials studying any monoclonal anti-NGF antibody at any dose/phase. Excluded studies were those where participants received NSAIDs or analgesics other than anti-NGF antibodies. The Jadad Scale score was used to assess the quality of the included studies. Results Thirteen studies were included in the analysis, involving 8145 participants with a diagnosis of hip and/or knee osteoarthritis. Anti-NGF antibody treatment was associated with a significant improvement in all Western Ontario and McMaster Universities Arthritis Index (WOMAC) indices when compared to placebo. These agents were not associated with a significantly increased incidence of serious adverse events but were associated with significant increases in therapy discontinuation due to adverse events or side effects (e.g., peripheral neuropathy). Conclusions Future randomized clinical trials are needed to characterize the overall risk-to-benefit ratio of anti-NGF antibodies in managing pain associated with OA, particularly with long-term use, in order to verify their efficacy and safety in clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|